In conclusion, our study, conducted through in vitro and in vivo experiments, underscores the potential of AB23A in ameliorating hepatic steatosis, likely via GRP94 inhibition, consequently impeding ERS and ERAD processes while restoring ER equilibrium (Figure 7). Here, HSP90B1 is linked to Hepatic steatosis.